For many years, immunotherapies such as CAR-T cell therapy and immune checkpoint inhibitors have primarily focused on activating type-1 immunity to eliminate cancer cells. In contrast, type-2 immunity, typically known for responding to parasitic infections, has traditionally been viewed as antagonistic to type-1 immunity and, consequently, as a promoter of tumor progression.

Leman Biotech Co., Ltd. (hereinafter referred to as "Leman Biotech"), a clinical-stage biotechnology company dedicated to the research, development, production, and commercialization of innovative metabolic immunotherapies, recently announced the successful treatment of the first pediatric patient enrolled in its investigator-initiated clinical trial (IIT). The patient, treated with an extremely low dose (1% of the conventional dose), achieved complete remission (CR) and was discharged without complications.

Leman Biotech Co., Ltd. (hereinafter referred to as "Leman Biotech"), a clinical-stage biotechnology company dedicated to the research, development, production, and commercialization of innovative metabolic immunotherapies, is pleased to announce the completion of new financing totaling USD 7 million in Angel+ and Angel++ rounds. New shareholders include Fuho Capital, Yunfan Technology Investment, and private financial investors, while original shareholders Tiantu Capital and XtalPi continue to support Leman Biotech. Additionally, Leman Biotech and its metabolically enhanced CAR-T projects have received various non dilutive grants amounting to approximately USD 2.7 million. To date, Leman Biotech has secured around USD 20 million in angel financing and project funding. This financing will primarily support the IND application of metabolically enhanced CAR-T cell therapy and the acceleration of clinical research of metabolically enhanced cell therapies for solid tumors.

On March 26, 2024, the kick-off meeting of the metabolically enhanced CD19 CAR-T cell (Meta10-19 injection) IIT clinical study project, developed by Leman Biotech Co., Ltd. (hereinafter referred to as "Leman Biotech"), was held in the Hubin Campus of the Children's Hospital Affiliated to Zhejiang University School of Medicine (hereinafter referred to as "Zhejiang University Children's Hospital").

Lausanne, April 21, 2024 - Leman Biotech, a clinical-stage biotechnology company focusing on the development, production, and commercialization of innovative metabolic immunotherapies, will deliver an oral presentation at the 27^th American Society of Gene and Cell Therapy (ASGCT) annual meeting, to be held in Baltimore, MD, from May 7th to 11th, 2024. We will present UPDATED clinical results from our first-in-human investigator-initiated clinical trials for Metabolically Armed CD19 CAR-T Cell therapy for relapsed or refractory B cell hematological malignancies. Our Associate Director of R&D Dr. Jingjing Ren will deliver the presentation.

Lausanne, March 27, 2024 - Leman Biotech, a clinical-stage biotechnology company focusing on the development, production, and commercialization of innovative metabolic immunotherapies, will deliver an oral presentation at the American Association of Cancer Research (AACR) annual meeting, to be held in San Diego, CA, from April 5th to 10th, 2024. We will present clinical results from our first-in-human investigator-initiated clinical trials for Metabolically Armed CD19 CAR-T Cell therapy for relapsed or refractory B cell hematological malignancies. Our Co-Founder and President Prof. Li Tang and Translational Research Director of our Swiss Research Center Dr. Karthik Sathiyanadan will attend the meeting. Our Associate Director of R&D Dr. Jingjing Ren will deliver the presentation.

On January 2, 2024, Prof. Li Tang and Dr. Yugang Guo, co-founders of Leman Biotech, published a paper in the top international academic journal Nature Biotechnology (IF=68), titled "IL-10-expressing CAR-T cells resist dysfunction and mediate durable clearance of solid tumors and metastases". The paper comprehensively reveals the preclinical research results of metabolically enhanced Meta 10 CAR-T therapy for solid tumors. The relevant findings suggest that Meta 10 CAR-T has enormous potential for curing solid tumors.

Leman Biotech was invited to participate in the Swiss Group for Clinical Cancer Research (SAKK)'s Cellular Therapies Workshop held as part of the 6th annual Swiss Oncology and Hematology Congress.Leman Biotech was one of four Top Swiss companies invited to present in the sessions: "Engineered Cells" and "Manufacturing Devices & Technology," showcasing their cutting-edge technologies and advancements in cell therapy development. Prof. Dr. George Coukos had previously given a welcome note and opened the session.